Understanding RUNX1 Mutations in Acute Myeloid Leukemia
Assessing lineage infidelity, oncogenic cooperativity and dependency in RUNX1-mutant acute myeloid leukemia
This research aims to better understand how specific genetic changes, called RUNX1 mutations, contribute to acute myeloid leukemia (AML) and make it harder to treat.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11105898 on NIH RePORTER |
What this research studies
Patients with acute myeloid leukemia (AML) who have a specific change in their RUNX1 gene often face challenges because their cancer can be resistant to standard treatments and has a poorer outlook. We know that these RUNX1 mutations can cause the cancer cells to behave unusually, a process called 'lineage infidelity,' which might be why treatments don't work as well. However, we don't fully understand how these mutations lead to this behavior or how they contribute to the disease's progression. This project will use advanced models to explore the specific roles of RUNX1 mutations, especially when they occur alongside other genetic changes like NRAS mutations, to uncover how they drive AML and its resistance to therapy.
Who could benefit from this research
Good fit: This foundational research is relevant to patients diagnosed with acute myeloid leukemia (AML), particularly those whose cancer cells carry RUNX1 mutations.
Not a fit: Patients whose acute myeloid leukemia does not involve RUNX1 mutations may not directly benefit from the specific findings of this particular research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to target and treat RUNX1-mutant AML, potentially improving outcomes for patients who currently have limited options.
How similar studies have performed: While the specific mechanisms are not fully understood, other studies have highlighted the importance of genetic mutations in cancer development and treatment resistance, suggesting this approach is promising.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Xiao, Wenbin — Sloan-Kettering Inst Can Research
- Study coordinator: Xiao, Wenbin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.